The Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS) was the first landmark trial that validated the inflammatory hypothesis in atherosclerosis, where interleukin-1β (IL-1β) antagonism was shown to decrease major adverse cardiovascular events (MACE) independent of lipid-lowering [3]. This evidence concerns the gene IL1B and atherosclerosis.